Significant correlation shown between blood levels and symptom relief; TH104 was well tolerated with no unexpected ...

Interim results from the ongoing GLISTEN trial of linerixibat, GSK's targeted inhibitor of the ileal bile acid transporter ...

Ipsen presents 3 late-breaking presentations and 8 abstracts across rare cholestatic liver disease portfolio at AASLD 2024 ...

The drugmaker put the idea to the test in a phase 3 trial that randomized PBC patients with moderate to severe itch to ...

GSK (NYSE:GSK) said a Phase 3 study of its drug linerixibat in the treatment of relentless itching in patients with primary ...

Resubmission includes new pivotal data which confirm Dupixent significantly reduced itch and hive activityMore than 300,000 people in the U.S.

Dupixent sBLA accepted for FDA review for the treatment of chronic spontaneous urticaria Resubmission includes new pivotal data which confirm ...

Surveys were conducted across several European countries to assess the prevalence, symptoms, treatment, and impact of CKD-aP on patients' quality of life. Findings are clear: over two-thirds of CKD-aP ...

GSK announces positive results from GLISTEN phase III trial of linerixibat in adults with cholestatic pruritus (relentless itch) associated with PBC: London, UK Wednesday, Novembe ...

Depending on the cause of your itchy skin, you may benefit from using more than one treatment. This may be especially needed in cases of chronic itching. For example, chronic itchiness related to ...

Itchy breasts and nipples can be an uncomfortable experience that disrupts daily life. While occasional itching may seem ...

No new safety findings were observed. The most common treatment-emergent adverse events (>10 percent) occurring more ...